OSU 6162

Arvid Carlsson Research AB · Phase 2 active Small molecule

At a glance

Generic name	OSU 6162
Also known as	OSU6162-HCl, PNU-9639 1A, PNU-9639
Sponsor	Arvid Carlsson Research AB
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

OSU6162 as add-on in SSRI/SNRI-resistant Depression (PHASE2)
OSU6162 in Bipolar Depression (OBID) (PHASE2)
Study Evaluating Efficacy and Safety of OSU6162 in the Treatment of Residual Symptoms After Stroke (PHASE2)
Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OSU 6162 CI brief — competitive landscape report
OSU 6162 updates RSS · CI watch RSS
Arvid Carlsson Research AB portfolio CI